

AMENDMENTS TO THE CLAIMS:

The following listing of claims will replace all prior versions and listings of claims in the application:

1-37. (Cancelled)

38. (Currently amended) A composition comprising a modified GPI molecule, or a derivative or an equivalent thereof which induces an immune response directed to a micro-organism GPI inositolglycan domain but is incapable of inducing an immune response directed to a lipidic domain of said GPI, and wherein the derivative or equivalent comprises at least three residues of the core glycan of the modified GPI molecule.

39-53. (Cancelled)

54. (Previously presented) A composition according to claim 38, wherein the lipidic domain in the modified GPI molecule is incapable of inducing or eliciting an immune response directed to a GPI lipid domain.

55. (Previously presented) A composition according to claim 38 or 54, wherein said modified GPI molecule is the inositolglycan domain portion of GPI or a derivative or equivalent thereof.

56. (Previously presented) A composition according to claim 55, wherein said modified GPI molecule is a modified parasite GPI molecule or derivative or equivalent thereof.

57. (Previously presented) A composition according to claim 56, wherein said parasite is *Plasmodium*.

58. (Previously presented) A composition according to claim 57, wherein said *Plasmodium* is *P. falciparum*.

59. (Previously presented) A composition according to claim 55, wherein said GPI inositolglycan domain comprises the structure ethanolamine-phosphate-(Man α 1,2)-Man α 1,2Man α 1,6Man α 1,4GlcN-myo-inositol phosphoglycerol or a derivative or equivalent thereof.

60. (Previously presented) A composition according to claim 55, wherein said GPI inositolglycan domain comprises the structure

X1-X2-X3-X4-ethanolamine-phosphate-(Man α 1,2)-Man α 1,2Man α 1,6Man α 1,4GlcN-myo-inositol phosphoglycerol

wherein X1, X2, X3 and X4 are any 4 amino acids, or derivative or equivalent of said GPI inositolglycan domain.

61. (Previously presented) A composition according to claim 55, wherein said GPI inositolglycan domain comprises the structure

EtN-P-[M α 2]M α 2 M α 6 M α 4G α 6Ino
 EtN-P-[M α 2][G]M α 2 M α 6 M α 4G α 6Ino
 EtN-P-[M α 2][X]M α 2M α 6M α 4G α 6Ino
 EtN-P-[M α 2][EtN-P]M α 2M α 6 M α 4G α 6Ino
 EtN-P-M α 2 M α 6 M α 4G
 M α 2 M α 6 M α G
 EtN-P-M α 2 M α 6 M
 EtN-P-[M α 2][G]M α 2 M α 6 M α 4G
 EtN-P-[M α 2][X]M α 2 M α 6 M α 4G
 EtN-P-[M α 2][EtN-P]M α 2 M α 6 M α 4G
 M α 2 [M α 2][G]M α 2 M α 6 M α 4G
 M α 2 [M α 2][X]M α 2 M α 6 M α 4G
 M α 2 [M α 2][EtN-P]M α 6 M α 4G
 M α 6 M α 4G α 6Ino
 M α 2 M α 6 M α 4G α 6Ino
 M α 2 [M α 2]M α 6 M α 4G α 6Ino

Mo2 [Mo2][G]Mo6 Mo4Gα6Ino
 Mo2 [Mo2][X]Mo6 Mo4Gα6Ino
 EtN-P-[Mo2][G]Mo2 Mo6 M
 EtN-P-[Mo2][X]Mo2 Mo6 M
 EtN-P-[Mo2][EtN-P]Mo2 Mo6 M
 Mo2 [Mo2][G]Mo2 Mo6 M
 Mo2 [Mo2][X]Mo2 Mo6 M
 Mo2 [Mo2][EtN-P]Mo6 M
 Mo2 Mo6 M
 Mo6 Mo4G
 EtN-P-[Mo2] [G]Mo2 M
 EtN-P-[Mo2][X]Mo2 M
 EtN-P-[Mo2][EtN-P]Mo2 M

or derivative or equivalent thereof wherein EtN is ethanolamine, P is phosphate, M is mannose, G is non-N-acetylated glucosamine, [G] is any non-N-acetylated hexosamine, Ino is inositol or inositol-phosphoglycerol, [X] is any other substitute, α represent α-linkages which may be substituted with β-linkages wherever required, and numeric values represent positional linkages which may be substituted with any other positional linkages as required.